Home  > News

BioVaria 2010 Meets Increasing Demand from Industry and Venture Capitalists for Life-Science IP

BioVaria Spin-off Award goes to iThera Medical GmbH

22 April 2010, Munich, Germany – Thirteen European technology transfer organizations from Germany, Austria, France and Norway teamed up this year for BioVaria 2010, presenting over 50 licensable biopharmaceutical inventions and eight promising spin-offs to business developers and investors from the international biopharmaceutical industry. Despite the ongoing airspace restrictions, 90 percent of the presentations were held as scheduled.

‘We are impressed how many delegates have spared no pains to get here – be it by bus, train or car,’ said Christian Stein, CEO from Ascenion in his opening address. ‘We are particularly proud to have technology transfer partners from other European nations on board this year. Together with the continued support from industry and VC investors, we regard this as a strong endorsement for the idea behind BioVaria and as a vote of confidence for what we hope to create: an internationally renowned marketplace for Europe’s top life-science inventions originating from publicly funded research.’

For both, industry and academia, BioVaria provides a unique opportunity to meet and initiate partnerships for the development of promising early-stage projects. In four presentation streams, commercial opportunities in the fields of cancer, autoimmunity, inflammation, cardiovascular and other diseases were presented, with each stream being followed by lively discussions between inventors and potential licensees in the exhibition room.

New in 2010, was the Spin-off Panel moderated by Axel Polack, General Partner at TVM Capital. Eight selected spin-offs were invited to briefly introduce themselves and then challenged with exacting questions from a jury of seasoned managers and investors. Subsequently, the jury selected the most convincing candidate in terms of team, technology and business concept as winner of the BioVaria Spin-off Award worth EUR 3,000. The prize went to iThera Medical GmbH, a start-up that has recently been spun out of the Helmholtz Zentrum Munich to develop and commercialize an innovative molecular photonic imaging technology enabling the non-invasive analysis of tissues or biomarkers in vivo.

 ‘It was primarily the disruptive potential of iThera’s technology that convinced the jury,’ Axel Polack commented during the award ceremony, ‘although it has been hard to make a decision. We have seen many highly innovative and commercially attractive projects this day, not only during the Spin-off Panel, but also during the presentation streams and the poster exhibition.’

The stage is already set for BioVaria 2011: It will take place on 24 May 2011 in Munich, probably in conjunction with the ‘German Biotechnology Days’ (Deutsche Biotechnologietage) to be held on 25–26 May 2011.

‘The synchronisation of both events is part of our strategy to further increase the attractiveness of BioVaria to its audiences’, Peter Ruile, COO of Ascenion and coordinator of BioVaria commented. ‘We will also continue along our path of gradually extending the range of technology transfer partners to embrace additional European core markets.’


 BioVaria’s technologies, presentations and spin-off profiles are available for download at www.biovaria.org.

About BioVaria

 BioVaria was originally established as a nationwide biopharmaceutical showcasing event presenting top licensing opportunities from a broad range of public research institutions and universities to international industry. The concept received a strong positive response from research, technology transfer and industry: In 2008, over 150 delegates participated, many interactions were initiated and most of these are still ongoing, first deals have been closed and a start-up founded. Building on these results, the organizers were able to broaden the range of participating technology transfer organizations and potential licensees in 2009. In 2010, BioVaria is providing access to technology transfer partners from all over Europe for the first time. Also new in 2010 is the Spin-Off Marketplace, featuring some of Europe’s most promising entrepreneurial biotech companies.  

BioVaria 2010 is organized by Ascenion and its partners Austria Wirtschaftsservice Gesellschaft mbH, Bayerische Patentallianz GmbH, Birkeland Innovation, EMBLEM Technology Transfer GmbH, FIST S.A. (France Innovation Scientifique & Transfert), Fraunhofer Group for Life Sciences, IPAL GmbH, IP Bewertungs AG, Life Science Inkubator GmbH, Max Planck Innovation GmbH, National Genome Research Network and PROvendis GmbH.

The event is sponsored by the Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology; Boehringer Ingelheim Pharma GmbH & Co. KG; Hertin - IP Law Firm; Life Sciences Partners; Merck & Co; Merck Serono; TEVA Pharmaceutical Industries Ltd.; TVM Capital GmbH, and Vossius & Partner.

Communication partner is KONOCOM.

Media partners are B2Bioworld, Biotech Finances, MedTrack, Pharmalicensing and transkript 

Network partners are BioM AG and Tech Transfer Summit Ltd.